Facet Biotech
Fang Yuni is a highly experienced Principal Scientist at Abbott Biotherapeutics Corp. since December 2008, with a robust background in bioanalytical ligand binding assays for monoclonal antibodies under GLP compliance. Responsibilities include the design, development, validation, and implementation of assays to assess pharmacokinetic/toxicokinetic and immunogenicity profiles. Previously, Fang served as a Senior Scientist at Abbott Laboratories and PDL BioPharma, contributing significantly to IND filing processes and project team participation. Education includes a Ph.D.
This person is not in any teams
Facet Biotech
With several products currently in the clinic and a compelling long-term vision for our future, Facet Biotech is a small but sophisticated biotechnology company. Combining our expertise in antibody engineering with a disciplined, biology-driven research approach, our company is dedicated to advancing our current pipeline of four clinical-stage products and leveraging our research and development capabilities to identify and develop new drugs. We are passionate and committed about the work that we do, and we share a common goal of developing therapeutics that will improve people’s lives. Facet Biotech Corporation launched in December 2008 as a spin-off from PDL BioPharma, Inc.